Aclaris Therapeutics (ACRS) President & COO receives 18,675 shares from RSU vesting

Rhea-AI Filing Summary

Aclaris Therapeutics President and COO Hugh M. Davis reported an equity compensation transaction involving restricted stock units (RSUs). On February 3, 2026, 18,675 RSUs converted into 18,675 shares of Aclaris Therapeutics common stock at an exercise price of $0 per share.

After this transaction, Davis directly owned 45,425 shares of common stock and 56,025 RSUs. Each RSU represents the right to receive one share of common stock. The RSUs underlying this transaction vest in four equal annual installments on the first through fourth anniversaries of February 3, 2025, subject to his continuous service.

Insider Trade Summary

18,675 shares exercised/converted

Mixed 2 txns

Insider Davis Hugh M.

Role President and COO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	18,675	$0.00	--
Exercise	Common Stock	18,675	$0.00	--

Holdings After Transaction: Restricted Stock Units — 56,025 shares (Direct); Common Stock — 45,425 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Hugh M.

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		M		18,675	A	(1)	45,425	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/03/2026		M			18,675	(2)	(2)	Common Stock	18,675	$0	56,025	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

2. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

	/s/ Matthew Rothman, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aclaris Therapeutics (ACRS) report for Hugh M. Davis?

Aclaris Therapeutics reported that President and COO Hugh M. Davis had 18,675 restricted stock units convert into 18,675 shares of common stock. This equity compensation event occurred on February 3, 2026 and was reported on a Form 4 insider filing.

How many Aclaris Therapeutics (ACRS) shares does Hugh M. Davis hold after this Form 4?

Following the reported transaction, Hugh M. Davis directly holds 45,425 shares of Aclaris Therapeutics common stock. In addition, he beneficially owns 56,025 restricted stock units, each representing a contingent right to receive one share of common stock upon vesting.

What does the 18,675 restricted stock unit transaction for Aclaris Therapeutics (ACRS) mean?

The transaction reflects the conversion of 18,675 restricted stock units into 18,675 common shares at an exercise price of $0 per share. It is a routine equity compensation event for the company’s President and COO, recorded with transaction code “M” on the Form 4.

How do Hugh M. Davis’s Aclaris Therapeutics (ACRS) RSUs vest over time?

The RSUs vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025. Vesting is conditioned on Hugh M. Davis maintaining continuous service with Aclaris Therapeutics on each applicable vesting date, according to the plan terms.

What is the relationship of Hugh M. Davis to Aclaris Therapeutics (ACRS)?

Hugh M. Davis serves as both a director and the President and COO of Aclaris Therapeutics. His dual role is disclosed in the Form 4, which reports his beneficial ownership and equity compensation activity in the company’s common stock and restricted stock units.

Was there a purchase price for the Aclaris Therapeutics (ACRS) RSU conversion?

The Form 4 shows an exercise price of $0 per share for the 18,675 restricted stock units converting into common stock. This indicates the shares were issued without cash payment, consistent with typical restricted stock unit settlement structures under equity compensation plans.